Clinical Trials Browser

dodecyl maltoside × 90 days × Clear all

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ